Education
About Us
Working with TipRanks
Follow Us
Aerovate Therapeutics, Inc. (AVTE)
:AVTE
Total Valuation
Aerovate Therapeutics has a market cap or net worth of $74.78M. The enterprise value is -$1.40M.
Market Cap$74.78M
Enterprise Value-$1.40M
Share Statistics
Aerovate Therapeutics has 28.99M shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding28.99M
Owened by Insiders51.18%
Owened by Instutions0.26%
Financial Efficiency
Aerovate Therapeutics’s return on equity (ROE) is -0.91 and return on invested capital (ROIC) is -97.05%.
Return on Equity (ROE)-91.10%
Return on Assets (ROA)-86.68%
Return on Invested Capital (ROIC)-97.05%
Return on Capital Employed (ROCE)-97.51%
Revenue Per Employee$0
Profits Per Employee-$2,320,933.333
Employee Count30
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Aerovate Therapeutics is -1.09. Aerovate Therapeutics’s PEG ratio is 0.07.
PE Ratio-1.09
PS Ratio0.00
PB Ratio0.99
Price to Fair Value0.99
Price to FCF-1.06
Price to Operating Cash Flow-1.06
PEG Ratio0.07
Income Statement
In the last 12 months, Aerovate Therapeutics had revenue of $0.00 and earned -$69.63M in profits. Earnings per share was -$2.44.
Revenue$0.00
Gross Profit-$56.00K
Operating Income-$74.60M
Pretax Income-$69.57M
Net Income-$69.63M
EBITDA-74.31M
Earnings Per Share (EPS)-2.44
Cash Flow
In the last 12 months, operating cash flow was -$71.20M and capital expenditures $0.00, giving a free cash flow of -$71.20M billion.
Operating Cash Flow-$71.20M
Free Cash Flow-$71.20M
Free Cash Flow per Share-$2.46
Dividends & Yields
Aerovate Therapeutics pays an annual dividend of $2.40, resulting in a dividend yield of
Dividend Per Share$2.40
Dividend Yield
Payout Ratio
Free Cash Flow Yield-94.00%
Earnings Yield-91.93%
Stock Price Statistics
Beta1.18
52-Week Price Change-89.46%
50-Day Moving Average2.49
200-Day Moving Average2.27
Relative Strength Index (RSI)52.00
Average Volume (3m)103.86K
Important Dates
Aerovate Therapeutics upcoming earnings date is May 19, 2025, Before Open.
Last Earnings DateMar 26, 2025
Next Earnings DateMay 19, 2025
Ex-Dividend DateApr 25, 2025
Financial Position
Aerovate Therapeutics as a current ratio of 20.93, with Debt / Equity ratio of <0.01
Current Ratio20.93
Quick Ratio20.93
Debt to Market Cap0.00
Net Debt to EBITDA0.45
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Aerovate Therapeutics has paid $39.72K in taxes.
Income Tax$39.72K
Effective Tax Rate-0.08%
Enterprise Valuation
Aerovate Therapeutics EV to EBITDA ratio is -0.57, with an EV/FCF ratio of -0.60.
EV to Sales0.00
EV to EBITDA-0.57
EV to Free Cash Flow-0.60
EV to Operating Cash Flow-0.60
Balance Sheet
Aerovate Therapeutics has $78.62M in cash and marketable securities with $417.00K in debt, giving a net cash position of -$78.21M billion.
Cash & Marketable Securities$78.62M
Total Debt$417.00K
Net Cash-$78.21M
Net Cash Per Share-$2.70
Tangible Book Value Per Share$2.67
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Aerovate Therapeutics is , which is 11.43% higher than the current price. The consensus rating is
Price Target
Price Target Upside
Analyst Consensus
Analyst Count0
Revenue Growth Forecast
EPS Growth Forecast14.71%